CCI testing methods (dye ingress, helium leak, vacuum decay, microbial challenge) confirm that the sterile barrier system protects sterility. ISO 11607 references CCI methods; package validation must address transport hazards in addition to long-term stability. ISO 11607-1 covers the design and validation of sterile barrier systems, and ISO 11607-2 covers the forming, sealing and assembly processes. Deterministic methods such as vacuum decay and helium leak testing are preferred over probabilistic ones like dye ingress because they are more sensitive and repeatable. Distribution testing often follows ASTM D4169 or ISTA.

Why it matters

CCI failures are a leading cause of recalls and field corrections in sterile-packaged devices.

Common pitfalls

•Failing to integrate CCI testing into a comprehensive package validation plan can lead to regulatory non-compliance.
•Ignoring the impact of manufacturing process variations on CCI can result in compromised sterile barriers.
•Selecting CCI test methods that are not sensitive or appropriate for the specific device and package design can provide a false sense of security.
•Not considering the effects of transportation and handling stresses on CCI can lead to sterility breaches in the field.
•Delaying CCI testing until the final stages of design and manufacturing can lead to costly rework and project delays.

Sources

ISO 11607-1 · ISO
ISO 13485 Standard Page · ISO
GHTF/IMDRF Process Validation Guidance · IMDRF/GHTF

Open full page

Select term B to compare.

Why compare MedTech terms side by side?

MedTech terminology is full of pairs that look interchangeable but carry very different regulatory, clinical, and commercial consequences. Picking the wrong framework, pathway, or standard early in a project can add months to a submission, invalidate clinical evidence, or trigger an audit finding. Side-by-side comparison is the fastest way to surface those differences before they become costly mistakes.

Each comparison on this page pulls from the same vendor-neutral, sourced definitions used throughout the MedTech Terms glossary. You see the one-line summary, the formal definition, why it matters in practice, common pitfalls, and the primary sources (FDA guidance, EU MDR/IVDR articles, ISO/IEC standards, MDCG documents, IMDRF principles) that back each entry. That makes the comparison defensible in regulatory strategy memos, design reviews, and submission narratives.

Common comparison patterns

Regulatory pathway choice - 510(k) vs PMA, 510(k) vs De Novo, Abbreviated vs Special 510(k).
Quality systems - QSR vs ISO 13485, QMSR vs QSR.
Software classification - SaMD vs SiMD, Locked vs adaptive AI.
EU frameworks - MDR vs IVDR, CE Mark vs UKCA.
Cybersecurity artifacts - SPDX vs CycloneDX SBOM, CVE vs CVSS.
Post-market actions - Recall vs field action, Removal vs correction.

How to use this tool

Pick term A and term B from the dropdowns, or click a preset above. The URL updates with both slugs so you can bookmark or share the exact comparison with a colleague, a notified body reviewer, or your regulatory consultant. Click Open full page on either side for the complete entry, including FAQs, related terms, and the full citation list. If you are not sure which term to start with, browse the Categories view or the A-Z index.

MedTech Terms is a vendor-neutral community resource sponsored by Blue Goat Cyber. Definitions are written for educational use and are not legal or regulatory advice.